Matching Treatments to Cognitive Deficits in Offenders With Substance Use Disorders
NCT06981351, Not applicable, Recruiting, The Mind Research Network
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Matching Treatments to Cognitive Deficits in Offenders With Substance Use Disorders | ClinicalTrials.gov |
| NCT number | NCT06981351 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 288 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | The Mind Research Network | ClinicalTrials.gov |
| Conditions | Antisocial Behavior | ClinicalTrials.gov |
| Interventions | Attention to Context (ATC) training, Affective Cognitive Control (ACC) training | ClinicalTrials.gov |
| First posted | 2025-05-20 | ClinicalTrials.gov |
| Last updated | 2026-08-17 | ClinicalTrials.gov |
Registered outcomes 10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Cognitive task performance - Stroop | From enrollment to end of treatment at six weeks | Stroop task. Performance is quantified by number of correct responses (0 - 100)%. | ClinicalTrials.gov |
| Primary | Cognitive task performance - Lexical Decision Making | From enrollment to end of treatment at six weeks | Lexical Decision Making task. Performance is quantified by number of correct responses (0 - 100%). | ClinicalTrials.gov |
| Primary | Cognitive task performance - Delay Discounting | From enrollment to end of treatment at six weeks | Delay Discounting task. Performance is quantified quantified by calculating where the answers place the respondent amid reference discounting curves. Range 0.0-0.5. | ClinicalTrials.gov |
| Primary | Functional MRI - Go/NoGo task performance | Change assessed from enrollment to end of treatment at six weeks | Functional MRI task performance (Go/NoGo task). Performance is quantified by the number of 'false alarms' (responding to the NoGo stimulus). Range 0-39. | ClinicalTrials.gov |
| Primary | Functional MRI - Go/Nogo brain response | Activity assessed during MRI scan. Change assessed from enrollment to end of treatment at six weeks | Change (i.e. increased or decreased) in functional brain response (Blood Oxygen Level Dependent/BOLD) in region of interest (anterior cingulate) assessed using Statistical Parametric Mapping (SPM). | ClinicalTrials.gov |
| Primary | Real-World Outcomes - Substance use (TLFB) | From enrollment to six months post-release from incarceration | Substance use. Assessed using the timeline follow back (TLFB) - calendar recording dates of use for stimulant drugs. | ClinicalTrials.gov |
| Primary | Real-World Outcomes - Substance use (ASE) | From enrollment to six months post-release from incarceration | Substance use. Assessed using the Abstinence Self Efficacy scale (higher scores indicate greater difficulty with abstinence). Range 0-4. | ClinicalTrials.gov |
| Primary | Real-World Outcomes - Substance use (DUDIT) | From enrollment to six months post-release from incarceration | Substance use. Assessed using the Drug Use Disorders Identification test (higher scores indicate more/severe substance use). Range 0-44. | ClinicalTrials.gov |
| Primary | Real-World Outcomes - Criminal behavior | From enrollment to six months post-release from incarceration | Criminal behavior. Assessed using the Crime Inventory - records the number of instances of criminal behavior | ClinicalTrials.gov |
| Primary | Risky Impulsive Self-Destructive Behavior | From enrollment to six months post-release from incarceration | The RISQ questionnaire measures risky, impulsive, and self-destructive behaviors in 8 domains (aggression, self-harm, gambling, impulsive spending/driving, impulsive eating, risky sex, illegal behavior, and alcohol use). For each behavior, respondents note the number of times they have engaged in the behavior in their lifetime. Higher scores indicate more severe risky, impulsive, and self destructive behavior. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Delay Discounting | Primary outcome | ConductCognition |
| Go/No-Go Task | Primary outcome | ConductCognition |
| Lexical Decision Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.3.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 4a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
Release trials-2026-11-12-0.3.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.